Biomarkers /
ERCC2
Overview
Excision repair cross-complementation group 2 (ERCC2) is a gene that encodes a protein that functions in the nucleotide excision repair pathway. Missense mutations and silent mutations are observed in cancers such as colon cancer, stomach cancer, and ovarian cancer.
ERCC2 is altered in 1.97% of all cancers with bladder urothelial carcinoma, lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in ERCC2 are ERCC2 Mutation (1.56%), ERCC2 Amplification (0.24%), ERCC2 Loss (0.11%), ERCC2 N238S (0.06%), and ERCC2 D732G (0.07%) [3].
Clinical Trials
Significance of ERCC2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.